The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature
Open accessAbstract
There must be something unique about a class of drugs (discovered and developed in the mid-1940s) where there are more than 130 ongoing clinical trials currently listed. Tetracyclines were developed as a result of the screening of soil samples for antibiotic organisms. The first of these compounds chlortetracycline was introduced in 1948. Soon after their development tetracyclines were found to be highly effective against various pathogens including rickettsiae, Gram-positive, and Gram-negative bacteria, thus, becoming a class of broad-spectrum antibiotics. The mechanism of action of tetracyclines is thought to be related to the inhibition of protein synthesis by binding to the 30S bacterial ribosome. Tetracyclines are also an effective anti-malarial drug. Over time, many other “protective” actions have been described for tetracyclines. Minocycline, which can readily cross cell membranes, is known to be a potent anti-apoptotic agent. Its mechanism of action appears to relate to specific effects exerted on apoptosis signaling pathways. Another tetracycline, doxycycline is known to exert antiprotease activities. Doxycycline can inhibit matrix metalloproteinases, which contribute to tissue destruction activities in diseases such as gingivitis. A large body of literature has provided additional evidence for the “beneficial” actions of tetracyclines, including their ability to act as oxygen radical scavengers and anti-inflammatory agents. This increasing volume of published work and ongoing clinical trials supports the notion that a more systematic examination of their possible therapeutic uses is warranted. This review provides a summary of tetracycline's multiple mechanisms of action and while using the effects on the heart as an example, this review also notes their potential to benefit patients suffering from various pathologies such as cancer, Rosacea, and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“Tet regulatory system, an important transcriptional regulation tool that is used extensively for targeted gene regulation in eukaryotes (35).”
BackgroundMolecular characterization of mitochondrial apoptosis-inducing factor
Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., et al. (1999) · Nature · doi:10.1038/17135 · Cited by 4,060
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Nagase, H., & Woessner, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21491 · Cited by 3,912
Cytochrome C -Mediated Apoptosis
Jiang, X., & Wang, X. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073706 · Cited by 1,357
Halestrap, A. (2004) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00533-9 · Cited by 1,222
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,067
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,051
Many cuts to ruin: a comprehensive update of caspase substrates
Fischer, U., Jänicke, R. U., & Schulze-Osthoff, K. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401160 · Cited by 1,029
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 1×
“(101), it was found that MIN and DOX increased the survival of hippocampal neurons following global brain ischemia in gerbils, and this protection was associated with reduced caspase-1 expression.”
Background
Cited by
A brief history of the antibiotic era: lessons learned and challenges for the future
Aminov, R. I. (2010) · Frontiers in Microbiology · doi:10.3389/fmicb.2010.00134 · Cited by 1,628
Antibacterial Activity of Silver Nanoparticles: Structural Effects
Tang, S., & Zheng, J. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701503 · Cited by 1,205
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas
Cathcart, J., Pulkoski-Gross, A., & Cao, J. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2014.12.002 · Cited by 504
The history of the tetracyclines
Nelson, M. L., & Levy, S. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06354.x · Cited by 468
Tetracyclines metal complexation: Significance and fate of mutual existence in the environment
Pulicharla, R., Hegde, K., Brar, S. K., & Surampalli, R. Y. (2017) · Environmental Pollution · doi:10.1016/j.envpol.2016.12.017 · Cited by 278
Rethinking Dry Eye Disease: A Perspective on Clinical Implications
Bron, A. J., Tomlinson, A., Foulks, G. N., Pepose, J. S., Baudouin, C., Geerling, G., Nichols, K. K., & Lemp, M. A. (2014) · The Ocular Surface · doi:10.1016/j.jtos.2014.02.002 · Cited by 256
Maezawa, I., Nguyen, H. M., Di Lucente, J., Jenkins, D. P., Singh, V., Hilt, S., Kim, K., Rangaraju, S., Levey, A. I., Wulff, H., et al. (2018) · Brain · doi:10.1093/brain/awx346 · Cited by 125
“However, the microglial contribution to hippocampal LTP is by no means conclusive in view of the pleotropic, non-microglial effects of minocycline (Griffin et al., 2010).”
BackgroundMetalloproteinase inhibition prevents inhibitory synapse reorganization and seizure genesis
Pollock, E., Everest, M., Brown, A., & Poulter, M. O. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.003 · Cited by 75
Non-antibiotic properties of tetracyclines and their clinical application in dermatology
Perret, L. J., & Tait, C. P. (2014) · Australasian Journal of Dermatology · doi:10.1111/ajd.12075 · Cited by 68
Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome
Batool, Z., Lomakin, I. B., Polikanov, Y. S., & Bunick, C. G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008671117 · Cited by 50
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Bortolanza, M., do Nascimento, G. C., Raisman‐Vozari, R., & Del‐Bel, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15439 · Cited by 33
Metadata
- Authors
- Griffin, M. O., Fricovsky, E., Ceballos, G., & Villarreal, F.
- Venue
- American Journal of Physiology-Cell Physiology
- Publisher
- American Physiological Society
- Published
- 2010-09
- Volume
- 299
- Issue
- 3
- Pages
- C539-C548
- ISSN
- 0363-6143 (ISSN-L)
- 1522-1563
- OpenAlex
- W2166673123
- Cited by
- 413
- References
- 86
- FWCI
- 13.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.